scholarly journals Prevalence of thyroid eye disease in Graves’ disease: A meta‐analysis and systematic review

2020 ◽  
Vol 93 (4) ◽  
pp. 363-374 ◽  
Author(s):  
Yip Han Chin ◽  
Cheng Han Ng ◽  
Ming Hui Lee ◽  
Jeffery Wei Heng Koh ◽  
Jolene Kiew ◽  
...  
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Thyroid Eye Disease ◽  
Eye Disease ◽  
Graves Disease

scholarly journals AB1043 AWARENESS OF THYROID EYE DISEASE, AN AUTOIMMUNE CONDITION, AMONG RHEUMATOLOGISTS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1813.1-1813
Author(s):  
B. Lamoreaux ◽  
M. Francis-Sedlak ◽  
R. Holt ◽  
J. Rosenbaum
Keyword(s):  
Rheumatoid Arthritis ◽  
Lupus Erythematosus ◽  
Granulomatosis With Polyangiitis ◽  
The United States ◽  
Thyroid Eye Disease ◽  
Eye Disease ◽  
Infusion Therapy ◽  
Graves Disease ◽  
Ocular Motility ◽  
Referral Patterns

Background:Autoimmune inflammatory conditions of the eye may be associated with rheumatic diseases such as rheumatoid arthritis, systemic lupus erythematosus, and granulomatosis with polyangiitis. This is also observed with thyroid eye disease (TED). Loss of immune tolerance to the thyroid stimulating hormone receptor has thyroidal consequences and nearly 40% of patients with Graves’ disease also have clinically evident Graves’ orbitopathy or TED.1TED results from tissue inflammation that causes retro orbital fat expansion2and extraocular muscle enlargement2and stiffening.3Because the orbital cavity is bony and of limited volume, proptosis and, in severe cases, optic nerve compression, can result. In many patients, muscle changes also cause ocular motility issues and double-vision. Because TED can have a similar presentation to other inflammatory orbital diseases (e.g., granulomatosis with polyangiitis) and Graves’ disease patients frequently have other autoimmune conditions (10% of Graves’s patients also have rheumatoid arthritis),4rheumatologists are likely to care for, or even diagnose, patients with TED.Objectives:This analysis sought to understand rheumatologists’ knowledge, and degree of participation in the treatment, of TED including referral patterns from ophthalmologists and endocrinologists for infusion therapies.Methods:Rheumatologists practicing in the United States attended an educational session and agreed to complete a 12-item survey regarding TED awareness, referral patterns, and management.Results:Of the 47 rheumatologists surveyed, 45 (96%) were familiar with TED. Ten (21%) physicians reported managing patients with TED, but the majority of physicians (62%) reported that they co-managed other autoimmune diseases in patients who also had TED. Additionally, 98% and 64% of polled rheumatologists had received referrals from ophthalmologists and endocrinologists, respectively, for autoimmune disease management or infusion therapy. Ophthalmology referrals for intravenous (IV) medication administration were most frequently for biologics (82%), but some referrals were also made for corticosteroids (2%) or other medication (13%) infusions. Only 23% of rheumatologists had administered a biologic specifically for TED (rituximab: 17%, tocilizumab: 2%, other: 4%), but 89% expressed an interest in administering a TED-specific monoclonal antibody therapy, awaiting FDA approval.Conclusion:Nearly all surveyed rheumatologists were aware of the signs and symptoms of TED, although most did not actively manage or administer medication for TED. Given the high level of interest in infusing novel, TED-specific biologics, rheumatologists may become an integral part of TED patient management with the approval of a new biologic, teprotumumab, for thyroid eye disease.References:[1]Bartley GB, et al.Am J Ophthalmol1996;121:284-90.[2]Forbes G, et al.AJNR Am J Neuroradiol1986;7:651-656.[3]Simonsz HJ, et al.Strabismus1994;2:197-218.[4]Cardenas Roldan J, et al.Arthritis2012 2012;864907.Disclosure of Interests:Brian LaMoreaux Shareholder of: Horizon Therapeutics, Employee of: Horizon Therapeutics, Megan Francis-Sedlak Shareholder of: Horizon Therapeutics, Employee of: Horizon Therapeutics, Robert Holt Shareholder of: Horizon Therapeutics, Employee of: Horizon Therapeutics, James Rosenbaum Consultant of: AbbVie, Corvus, Eyevensys, Gilead, Novartis, Janssen, Roche, UCB Pharma; royalties from UpToDate

Oxidative and antioxidative stress markers in dry eye disease: A systematic review and meta‐analysis

2021 ◽  
Author(s):  
Valentin Navel ◽  
Vincent Sapin ◽  
Fanny Henrioux ◽  
Loïc Blanchon ◽  
Antoine Labbé ◽  
...  
Keyword(s):  
Systematic Review ◽  
Dry Eye ◽  
Meta Analysis ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Stress Markers ◽  
Antioxidative Stress

Association between vitamin D and dry eye disease: A systematic review and meta-analysis of observational studies

2020 ◽  
Vol 43 (5) ◽  
pp. 418-425 ◽  
Author(s):  
Gholamreza Askari ◽  
Nahid Rafie ◽  
Maryam Miraghajani ◽  
Zahra Heidari ◽  
Arman Arab
Keyword(s):  
Systematic Review ◽  
Vitamin D ◽  
Dry Eye ◽  
Observational Studies ◽  
Meta Analysis ◽  
Dry Eye Disease ◽  
Eye Disease

scholarly journals Effects of Selenium Supplementation on Graves’ Disease: A Systematic Review and Meta-Analysis

2018 ◽  
Vol 2018 ◽  
pp. 1-10 ◽  
Author(s):  
Huijuan Zheng ◽  
Junping Wei ◽  
Liansheng Wang ◽  
Qiuhong Wang ◽  
Jing Zhao ◽  
...  
Keyword(s):  
Systematic Review ◽  
Thyroid Function ◽  
Meta Analysis ◽  
Selenium Supplementation ◽  
Control Group ◽  
Graves Disease ◽  
Cochrane Central Register ◽  
Placebo Administration ◽  
Increased Risk ◽  
Tsh Levels

Low selenium status is associated with increased risk of Graves’ disease (GD). While several trials have discussed the efficacy of selenium supplementation for thyroid function, in GD patients, the effectiveness of selenium intake as adjuvant therapy remains unclear. In this systematic review and meta-analysis, we aimed to determine the efficacy of selenium supplementation on thyroid function in GD patients. Two reviewers searched PubMed, Web of Science, the Cochrane Central Register of Controlled Trials, and four Chinese databases for studies published up to October 31, 2017. RCTs comparing the effect of selenium supplementation on thyroid hyperfunction in GD patients on antithyroid medication to placebo were included. Serum free thyroxine (FT4), free triiodothyronine (FT3), thyrotrophic hormone receptor antibody (TRAb), and thyroid-stimulating hormone (TSH) levels were assessed. Ten trials involving 796 patients were included. Random-effects meta-analyses in weighted mean difference (WMD) were performed for 3, 6, and 9 months of supplementation and compared to placebo administration. Selenium supplementation significantly decreased FT4 (WMD=-0.86 [confidence interval (CI)-1.20 to -0.53]; p=0.756; I2=0.0%) and FT3 (WMD=-0.34 [CI-0.66 to -0.02]; p=0.719; I2=0.0%) levels at 3 months, compared to placebo administration; these findings were consistent at 6 but not 9 months. TSH levels were more elevated in the group of patients taking selenium than in the control group at 3 and 6, but not 9 months. TRAb levels decreased at 6 but not 9 months. At 6 months, patients on selenium supplementation were more likely than controls to show improved thyroid function; however, the effect disappeared at 9 months. Whether these effects correlate with clinically relevant measures remains to be demonstrated.

Prevalence, incidence and future projection of diabetic eye disease in Europe: a systematic review and meta-analysis

2019 ◽  
Vol 35 (1) ◽  
pp. 11-23 ◽  
Author(s):  
Jeany Q. Li ◽  
Thomas Welchowski ◽  
Matthias Schmid ◽  
Julia Letow ◽  
Caroline Wolpers ◽  
...  
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Eye Disease ◽  
Future Projection ◽  
Diabetic Eye Disease

scholarly journals Corrigendum: The Efficacy and Safety of Qiming Granule for Dry Eye Disease: A Systematic Review and Meta-Analysis

2020 ◽  
Vol 11 ◽  
Author(s):  
Maoyi Yang ◽  
Zhipeng Hu ◽  
Rensong Yue ◽  
Liangjun Yang ◽  
Boxun Zhang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Dry Eye ◽  
Meta Analysis ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Efficacy And Safety

scholarly journals B-cell autoepitopes on the acetylcholinesterase-homologous region of human thyroglobulin: association with Graves' disease and thyroid eye disease

2001 ◽  
pp. 119-127 ◽  
Author(s):  
A Thrasyvoulides ◽  
M Sakarellos-Daitsiotis ◽  
G Philippou ◽  
A Souvatzoglou ◽  
C Sakarellos ◽  
...  
Keyword(s):  
Solid Phase ◽  
Significant Proportion ◽  
Terminal Region ◽  
Thyroid Eye Disease ◽  
Eye Disease ◽  
Homologous Region ◽  
Graves Disease ◽  
Healthy Controls ◽  
Autoimmune Thyroid Diseases ◽  
Autoimmune Thyroid

OBJECTIVE: Thyroglobulin (Tg) is a large autoantigen involved in autoimmune thyroid diseases. Tg epitopes have, so far, been identified within large peptides. In the present study, we used small synthetic peptides to finely map serological epitopes on the highly immunogenic C-terminal region of Tg. Homology of this region to acetylcholinesterase (AChE) has been implicated in the pathogenesis of thyroid eye disease (TED) through cross-reactive antibodies. METHODS: We tested total IgG purified from four pilot Graves' disease (GD) sera reactive with both Tg and AChE and from three healthy controls, for reactivity against overlapping 20mer peptides (pin synthesis) covering the sequence 2171-2748 of human Tg. Antibody-reactive peptides were subsequently synthesized by a solid-phase technique for confirmation with a large number of sera: 99 GD, 32 Hashimoto's thyroiditis (HT) and 45 healthy controls. RESULTS: Peptides TgP15, TgP26 and TgP41 (amino acids 2339-2358, 2471-2490 and 2651-2670 respectively) were found to be targets of autoantibodies on intact Tg, recognized by a statistically significant proportion of GD sera (22.2%, 35.4% and 30.3% respectively), compared with HT (0%, 15.6% and 6.3% respectively) and healthy controls (0%, 4.4% and 4.4% respectively). The majority of GD sera (56.6%) were positive for at least one of the three peptides. In GD, TgP26 reactivity was found to be associated with TED (48.6% with TED versus 25.5% without TED, P<0.05). CONCLUSION: Some epitopes on the C-terminal region of Tg are associated with GD. A subset of Tg-reactive autoantibodies, directed to this region, is associated with TED and may be involved in the development of the disease.

Prevalence of Dry Eye Disease in Africa: A Systematic Review and Meta-analysis

2020 ◽  
Vol 97 (12) ◽  
pp. 1089-1098
Author(s):  
Prince K. Akowuah ◽  
Emmanuel Kobia-Acquah
Keyword(s):  
Systematic Review ◽  
Dry Eye ◽  
Meta Analysis ◽  
Dry Eye Disease ◽  
Eye Disease

scholarly journals Cigarette smoking and thyroid eye disease: a systematic review

Eye ◽  
2006 ◽  
Vol 21 (9) ◽  
pp. 1135-1145 ◽  
Author(s):  
J Thornton ◽  
S P Kelly ◽  
R A Harrison ◽  
R Edwards
Keyword(s):  
Systematic Review ◽  
Cigarette Smoking ◽  
Thyroid Eye Disease ◽  
Eye Disease
Sign in / Sign up

Export Citation Format

Share Document